The
Transfusion News email came in today… I was rather surprised to read the last
article about artificial blood… I can remember being told that artificial blood
(as in something that carries oxygen and carbon dioxide about) was ready
for commercial production in 1981…
Mitapivat Trial Results in Adults with Pyruvate Kinase Deficiency Requiring Transfusions
 | | August 31, 2022 | | Pyruvate
kinase deficiency is a rare, congenital form of chronic hemolytic
anemia. Current treatments for pyruvate kinase deficiency, including RBC
transfusions and splenectomy, are supportive only and do not address
the metabolic defect of the disease. Mitapivat, however, is the first of
a new class of oral drugs that activates pyruvate kinase, the enzyme in
the RBC responsible for catalyzing the last step of glycolysis and
producing ATP necessary to maintain RBC health. [Read More] |
|
 | | In
this new Transfusion Science Webinar, Carla Dinardo, MD, PhD, explains
why the Hemolytic Disease of the Fetus and Newborn remains a challenge
despite the many advances made to either prevent, or diagnose and treat
HDFN and its complications. [Register Now] |
|
 | | August 24, 2022 | | Advantages
of artificial red blood cells (RBCs) include reduced risks of pathogens
and alloimmunization and greater storage time compared to standard
RBCs. Several artificial RBCs have been developed; however, they have
been associated with higher risks of myocardial infarction and death in
clinical trials. [Read More] |
|
No comments:
Post a Comment